ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FDBK Feedback Plc

60.50
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 60.50 60.00 61.00 60.50 60.50 60.50 14,770 07:44:37
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electronic Computers 1.03M -2.92M -0.2188 -2.77 8.07M
Feedback Plc is listed in the Electronic Computers sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 60.50p. Over the last year, Feedback shares have traded in a share price range of 58.00p to 150.00p.

Feedback currently has 13,334,659 shares in issue. The market capitalisation of Feedback is £8.07 million. Feedback has a price to earnings ratio (PE ratio) of -2.77.

Feedback Share Discussion Threads

Showing 7151 to 7171 of 14875 messages
Chat Pages: Latest  295  294  293  292  291  290  289  288  287  286  285  284  Older
DateSubjectAuthorDiscuss
17/10/2019
18:20
He did, Ged.

Herb, there's more on the following link if you want to get up to date.

lr2
17/10/2019
18:14
Thanks LR2

Didn't he say not in today's interview, Herb?

ged5
17/10/2019
18:10
Should this be RNS'd?
herb clark
17/10/2019
17:37
TexRAD Research+

In response to requests from users for more functionality to meet the changing needs of imaging research, we are delighted to announce a new add-on: TexRAD Research+.

This offers important additional information, providing all of the patented filtration-histogram features of TexRAD Research, with the additional measurement parameters of GLCM (Grey Level Co-occurence Matrix) and shape. TexRAD Research + offers a platform for comprehensive radiomics analysis.

TexRAD Research+ is available as a premium add-on to existing TexRAD users or can be specified as a complete package by new users.

For more information, visit the TexRAD pages of our website: TexRAD Research

TexRAD Research+ is available to order now. Contact us to find out more How to Order



Good to see they are charging for it and it can be ordered now.

lr2
17/10/2019
15:21
'Bleepa
@BleepaMe
"We are very encouraged by the response to Bleepa® having discussed this with senior NHS executives at NHS Expo. The feedback is that Bleepa® clearly has applications in individual hospital settings but also in community and cross site clinical sett'
TWITTER

hazl
17/10/2019
14:15
Ged, exactly. If bleepa gains traction in the U.K. I expect it will be taken out by a large global interest. Assuming it's IP is protected and it is unique. Exciting times ahead. Tidy, yes, placing stock is the issue currently.
ducatiman
17/10/2019
14:11
I reckon a bit of the last placing stock is being flipped. Cant be much left now.
tidy 2
17/10/2019
14:08
Bleepa® clearly has applications in individual hospital settings but also in community and cross site clinical settings.

Who's been for a scan and then an appointment with a doctor?

Doctor refers you to the Physio after several weeks waiting for the scan results.

The appointment with the Physio is delayed for some time, because they're waiting for results from the doctor who's too overburdened to send the notes/scan promptly.

Isn't this where Bleepa comes into play?

So the radiologist, GP and Physio all need Bleepa for this to work. Well that's 30 quid a month and I'm just one patient. :-)

ged5
17/10/2019
13:50
Dave, no worries. share price should climb steadily from here. The news is very encouraging.
ducatiman
17/10/2019
13:31
Don't forget.....


'The Company is in advanced discussions with NHS pilot sites whilst additionally pursuing a number of commercial opportunities within and outside the NHS, and hopes to commence Bleepa(R) pilot schemes in the near future.'

which suggests more news in the future,perhaps!

hazl
17/10/2019
13:30
So what is meant by community and cross site clinical settings?
ged5
17/10/2019
13:29
BLEEPA Tweet "We are very encouraged by the response to Bleepa® having discussed this with senior NHS executives at NHS Expo. The feedback is that Bleepa® clearly has applications in individual hospital settings but also in community and cross site clinical settings."ow.ly/NKYW50wNxCx
tidy 2
17/10/2019
13:28
BLEEPA Tweet"We are very encouraged by the response to Bleepa® having discussed this with senior NHS executives at NHS Expo. The feedback is that Bleepa® clearly has applications in individual hospital settings but also in community and cross site clinical settings."ow.ly/NKYW50wNxCx
tidy 2
17/10/2019
13:08
New thread? I can't see one.
ged5
17/10/2019
13:08
hazl

Just back online. I'll update it this evening. Not sure I want it as long as the other thread but more upto date news

dave4545
17/10/2019
12:43
Bleepa will help get rid of NHS waiting times which is one of the main aims of the government
tidy 2
17/10/2019
12:36
Looks like we've lost hazl to the other new thread. How sad.
ducatiman
17/10/2019
11:54
Thanks LR2. Added to header.

Was it a lie in the first place?

Anyway not done much for the share price Still a lot of hope in that interview.

ged5
17/10/2019
11:36
He actually says 'as a radiologist I would have loved to have seen that' in that clip. Doubling down on that lie then!
dplewis1
17/10/2019
11:29
Tom Oakley latest chat.
lr2
17/10/2019
11:18
Hazl, post 3681, I can't get access to that link. What settings does it mention, please?
ged5
Chat Pages: Latest  295  294  293  292  291  290  289  288  287  286  285  284  Older